AlphaTON Capital (ATON) Registration Filing summary

Company overview and business model

• Clinical-stage immuno-oncology company focused on developing first-in-class therapies targeting checkpoint resistance pathways to improve cancer treatment outcomes.

• Recent strategic shift includes pausing or discontinuing certain clinical programs due to funding constraints and seeking external financing for key subsidiaries.

• Exploring strategic alternatives such as asset partnerships, company sale, mergers, restructurings, or wind down.

• Operates as a British Virgin Islands business company, listed on NASDAQ since 2021.

Financial performance and metrics

• As of September 30, 2024, shareholders' equity was $695,000, below the $2.5 million NASDAQ minimum.

• Completed a $2.15 million private placement in January 2025 to address listing requirements.

Use of proceeds and capital allocation

• Net proceeds from offerings will be used for general corporate purposes, working capital, debt repayment, R&D, potential acquisitions, and strategic alternatives.

• Management has broad discretion over allocation; no specific amounts or timing determined.